Treatment with Teva Neuroscience, Inc.'s COPAXONE(R) Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis

KANSAS CITY, Mo.--(BUSINESS WIRE)--New data from a randomized, double-blind study showed that a combination of COPAXONE® (glatiramer acetate injection) along with the oral antibiotic minocycline reduced T1 Gadolinium (Gd)-enhancing lesions of the brain by 63 percent (p=0.08) in patients with active relapsing-remitting multiple sclerosis (RRMS), as measured by magnetic resonance imaging (MRI), compared to those receiving COPAXONE® alone. Additionally, the nine-month study demonstrated that treatment with COPAXONE® in combination with minocycline reduced the number of new T2 lesions in patients by 65 percent (p=0.06). These results trended toward but did not reach statistical significance.